| |
| |
|
| Insider
Information: |
Sharp Shalini |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
215,117 |
|
|
Indirect Shares
|
104,270 |
|
|
| Direct
Value |
$4,317,035 |
|
|
|
Indirect Value
|
$46,244 |
|
|
| Total
Shares |
319,387 |
|
|
| Total
Value |
$4,363,279 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 537.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agenus Inc |
AGEN |
Director |
2013-01-30 |
81,311 |
2015-09-28 |
104,270 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
EVP, Finance |
2020-10-14 |
97,812 |
|
0 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
35,000 |
2021-02-10 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2021-03-26 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
994 |
2024-05-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,424 |
2,424 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,546 |
4,970 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
– • – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,444 |
9,414 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
16,222 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
|
• • – |
2024-01-23 |
4 |
D |
$0.00 |
$0 |
D/D |
(16,222) |
0 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
AS |
$141.90 |
$156,943 |
D/D |
(1,106) |
994 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
2,100 |
0 |
- |
|
| NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
– • – |
2021-02-10 |
4 |
A |
$10.00 |
$100,000 |
D/D |
10,000 |
35,000 |
0 |
- |
|
| NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
– • – |
2021-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2014-01-30 |
4 |
B |
$21.00 |
$94,500 |
D/D |
4,500 |
84,255 |
2.74 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
See RemarksOfficer |
• – – |
2014-01-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
79,755 |
|
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2014-08-18 |
4 |
AS |
$53.97 |
$215,880 |
D/D |
(4,000) |
80,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2014-09-18 |
4 |
AS |
$56.00 |
$224,000 |
D/D |
(4,000) |
76,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2014-10-20 |
4 |
AS |
$46.02 |
$184,080 |
D/D |
(4,000) |
72,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2014-11-20 |
4 |
AS |
$44.07 |
$176,281 |
D/D |
(4,000) |
68,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2014-12-18 |
4 |
AS |
$44.82 |
$179,290 |
D/D |
(4,000) |
64,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-01-20 |
4 |
AS |
$51.24 |
$204,957 |
D/D |
(4,000) |
60,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-02-18 |
4 |
AS |
$53.93 |
$215,935 |
D/D |
(4,000) |
56,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-03-18 |
4 |
AS |
$61.45 |
$245,800 |
D/D |
(4,000) |
52,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-04-20 |
4 |
AS |
$61.14 |
$248,910 |
D/D |
(4,000) |
48,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-05-01 |
4 |
OE |
$0.82 |
$815 |
D/D |
1,000 |
49,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-05-18 |
4 |
AS |
$79.43 |
$317,720 |
D/D |
(4,000) |
45,255 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,400 |
49,655 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-06-18 |
4 |
AS |
$95.95 |
$384,340 |
D/D |
(4,000) |
45,655 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-07-20 |
4 |
AS |
$130.99 |
$508,532 |
D/D |
(3,854) |
41,801 |
0 |
- |
|
130 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
